The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SGMO | -45.45% | -93.91% | -42.86% | -96% |
| S&P | +14.5% | +93.32% | +14.09% | +346% |
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.
These exchange-traded funds track companies in this biotech space.
Here's an overview of the opportunities in gene editing and CRISPR technology.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $18.31M | 5042.1% |
| Gross Profit | $16.41M | 840.1% |
| Gross Margin | 89.64% | 712.4% |
| Market Cap | $132.84M | 78.7% |
| Market Cap / Employee | $0.73M | 0.0% |
| Employees | 183 | -54.8% |
| Net Income | -$19.99M | 44.7% |
| EBITDA | -$15.96M | 49.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $38.34M | 38.0% |
| Accounts Receivable | $0.37M | -36.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $23.46M | -19.4% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -67.79% | 51.6% |
| Return On Invested Capital | -108.78% | -35.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.18M | 32.4% |
| Operating Free Cash Flow | -$18.16M | 32.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.62 | 5.44 | 6.13 | 24.86 | 1831.67% |
| Price to Sales | 3.55 | 3.71 | 2.27 | 1.70 | -71.40% |
| Price to Tangible Book Value | 4.62 | 5.44 | 6.13 | 24.87 | 1831.74% |
| Enterprise Value to EBITDA | 16.47 | -8.08 | -5.31 | -7.78 | 229.24% |
| Return on Equity | -156.4% | -187.8% | -262.1% | -298.4% | 53.78% |
| Total Debt | $27.73M | $30.57M | $24.88M | $23.46M | -19.37% |
SGMO earnings call for the period ending October 3, 2021.
SGMO earnings call for the period ending June 3, 2021.
SGMO earnings call for the period ending March 31, 2021.
SGMO earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
